The duration of action of inhaled formoterol dry powder

British Journal of Clinical Practice

Volumn 50, Issue 8, 1996, Pages 446-449

  Brambilla, R ^c   Walters, E H ^a   Hendrick, D J ^b  

^a CIBA GEIGY LTD   (Switzerland)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; ETHANOLAMINE DERIVATIVE; FORMOTEROL; SALBUTAMOL;

ADULT; ARTICLE; ASTHMA; CHRONIC DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; INHALATIONAL DRUG ADMINISTRATION; LUNG FUNCTION TEST; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; PATIENT SATISFACTION; RANDOMIZED CONTROLLED TRIAL; TIME;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-AGONISTS; ADULT; ALBUTEROL; ASTHMA; BRONCHODILATOR AGENTS; CHRONIC DISEASE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ETHANOLAMINES; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT SATISFACTION; RESPIRATORY FUNCTION TESTS; TIME FACTORS;

EID: 0030333091     PISSN: 00070947     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Barnes PJ. New drugs for asthma. Eur Respir J 1993; 5: 1126-1136.
2. Bagg LR, Hughes TDT. Diurnal variation in peak expiratory flow in asthmatics. Eur J Respir Dis 1980; 61: 298-302.
3. Tattersfield AE. Clinical pharmacology of long-acting beta-receptor agonists. Life Sci 1993: 52: 2161-2169.
4. Lofdahl CG, Chung KF. Long acting heta2-adrenoceptor agonists: a new perspective in the treatment of asthma. Eitr Respir J 1991: 4: 218-226.
5. British Thoracic Society. Guidelines on the management of asthma. Thorax 1993; 48(2): S1-S24.
6. Faulds LD, Hollingshead LM, Goa KL. Formoterol: a review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease. Drugs 1991; 42: 115-137.
7. Derom E, Pauwels R, Van der Staeten M. Time course of the bronchodilating effect of inhaled formoterol. Eur Respir J 1989; 2(suppl 5): 392S.
8. Von Berg A, Berdel D. Formoterol and salbutamol metered aerosols: comparison of a new and established beta-2-agonist for their bronchodilating effects in the treatment of childhood bronchial asthma. Pediatr Pulmonol 1989; 7: 89-93.
9. Nolle D, Rolke M. Comparative trial of the acute bronchospasmolitic action of formoterol versus fenoterol over 12 hours. In: Sybrecht G, Ed. Formoterol: a new long acting bronchodilator. Toronto: Hans Hober Publishers, 1987,24-31.
10. Maesen FPV, Smeets JJ, Gubbelmans HLL, Zweers PGM A. Bronchodilator effect of inhaled formoterol vs salbutamol over 12 hours. Chest 1990; 9: 590-594.
11. Becker AB. Simons FER, Macmillan JL, Faridy T. Formoterol. a new long-acting selective beta2-adrenergic receptor agonist: double-blind comparison with salbutamol and placebo in children with asthma. ./ Allergy Clin Immunol 1989; 84: 891-895.
12. Graff-Lonnevig V, Browaldh L. Twelve hours' bronchodilating effect of inhaled formoterol in children with asthma: a double-blind cross-over study versus salbutamol. Clin Exp Allergy 1990; 20: 429-432.
13. Wallin A, Sanstrom T, Rosenhall L, Melander B. Time course and duration of bronchodilatation with formoterol dry powder in patients with stable asthma. Thorax 1993; 48: 611-614.
14. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis 1987; 136: 225-244.
15. Senn S. Cross-over trials in clinical research. Chichester: John Wiley. 1993, 109-119.